Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CBL-514 Injection for Reducing Convexity or Fullness of Abdominal Subcutaneous Fat [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety, tolerability, and preliminary efficacy of CBL-514 for reducing abdominal subcutaneous fat fullness; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cosmetic Fat Reduction
• Subcutaneous Fat Adiposity

Drugs mentioned

• CBL-514

Snippet

Sponsor: Caliway Biopharmaceuticals Co., Ltd. | Conditions: Subcutaneous Fat | Phase 2 | Status: COMPLETED